Not an actual patient.
Efficiency that lasts1
Just one dose every 3 months1
The dosing schedule aligns with AACE recommendations for triglyceride level testing—once every 3 months, or more frequently when necessary.1,2,*
Redemplo® (plozasiran) is self-administered as a single subcutaneous 25-mg injection every 3 months1
If a dose is missed, Redemplo® should be administered as soon as possible, and regular dosing should resume 3 months after administered dose.1
Redemplo should be administered in any of the following locations3:
Upper Arm
(when administered by caregiver)
Thigh
Abdomen
Are you ready to help your patients GO LO with Redemplo?
Not an actual patient.
Proven results in patients with FCS1
Not an actual patient.
Resources and support are available
AACE, American Association of Clinical Endocrinology; FCS, Familial Chylomicronemia Syndrome.
REFERENCES Collapse
Collapse
- Redemplo. Prescribing information. Arrowhead Pharmaceuticals, Inc.; 2025.
- Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224.
- Redemplo. Instructions for use. Arrowhead Pharmaceuticals, Inc.; 2025.
Indication & Important Safety Information Collapse
Collapse
INDICATION
REDEMPLO® (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None.
ADVERSE REACTIONS: Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and > 5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.
Please see full Prescribing Information for REDEMPLO.